传

Dr. Hong earned his Ph.D. in Microbiology and Immunology at Sun Yat-sen University and completed his postdoctoral training in both University of Southern California and the University of Texas MD Anderson Cancer Center. He developed dendritic cell vaccine and T cell therapy for both solid tumor and hematologic malignancy.

香港joine博士d the Department of Neurosurgery at McGovern Medical School at UTHealth. Dr. Hong’s research interest is to develop novel oncolytic HSV for glioblastoma therapy and in combination with immunotherapy such as dendritic cell and T cell therapy.

Dr. Hong has published more than 30 research articles in scientific journals includingJournal of Clinical Investigation,癌症研究beplay苹果手机能用吗,Clinical Cancer Research,Nature Communications，以及与溶瘤病毒和肿瘤免疫疗法有关的章节。

教育

医学学位，临床医学
中国安海医科大学
Masters of Science, Microbiology and Immunology
Sun Yat-sen University, China
博士学位，微生物学和免疫学
Sun Yat-sen University, China

Publications

Publication Information

BOOK CHAPTERS

1.当前克服对靶向疗法的抗性的应用。施普林格，康。ISBN：978-3-030-21476-0。

选定的发表期刊文章

1. Hong B, Jiang LF, Hu YS，et al. Application of oligonucleotide array technology for the rapid detection of pathogenic bacteria of foodborne infections. Journal of Microbiological Methods, 2004, 58(3):403-411.
2. Hong B, Ren W, Song XT, Kabler KE, Chen SY, Huang XF. Human SOCS1 Controls Immunostimulatory Activity of Monocyte-derived Dendritic Cells. Cancer Research, 2009, 69 (20): 8076-8084.
3. Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. Embryonic Stem Cells and Mammary Luminal Progenitors Directly Sense and Respond to Microbial Products. Stem Cells, 2009 27(7):1604-1615.
4. Song XT，Turnis Me，Zhou X，Zhu W，Hong B，Rollins L，Rabinovich B，Chen Sy，Rooney CM，GottschalkS。一种诱导Th1诱导的腺病毒疫苗，用于提高采用转移的T细胞。Molecular Therapy，2011年，19（1）：211-217。
5. Hong B，Song XT，Rollins L，Berry L，Huang XF，Chen Sy。树突状细胞中A20控制的粘膜和全身抗HIV免疫。临床研究杂志，2011，121（2）：739-751。
6. Hong B, Lee SH, Song XT, Jones L, Machida K, Huang XF, Chen SY. A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One. 2012, 7(11):e48614.
7. Hong B, Peng G, Berry L, Gottschalk S, Jung JU, Chen SY and Huang XF. Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Therapy, 2012, 19(8):818-827.
8. Wang L, Hong B, Jiang X, Jones L, Chen SY, Huang XF. A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One. 2012; 7(11):e48930.
9. Lu Y，Hong S，Li H，Park J，Hong B，Wang L，Zheng Y，Liu Z，Xu J，He J，Yang J，Yang J，Qian J，Yi Q. Th9细胞在体内促进抗肿瘤免疫反应。临床研究杂志，2012，122（11）：4160-4171。
10. He J，Liu Z，Zheng Y，Qian J，Li H，Lu Y，Xu J，Hong B，Zhang M，Lin P，Cai Z，Orlowski RZ，Kwak LW，Yi Q，Yang J. P38 Mapk In骨髓瘤细胞调节破骨细胞和成骨细胞活性，并诱导骨骼破坏。癌症研究，20beplay苹果手机能用吗12，72（24）：6393-6402。
11. Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One,2013;8(12):e82453
12. Lu Y, Hong B, Li H, Zheng, Y, Zhang M, Wang S, Qian J, Yi Q. Tumor-specific CD8+ Tc9 cells are superior effector than Tc1 cells for adoptive immunotherapy of cancers. Proceedings of the National Academy of Sciences, 2014, 111: 2265-2270.
13. Zhang M，Qian J，Lan Y，Lu Y，Li H，Hong B，Zheng Y，He J，Yang J，Yi Q.抗β2M单克隆抗体通过细胞和补体介导的细胞毒性杀死骨髓瘤细胞。Int J Cancer，2014，135（5）：1132-1141。
14. Park J，Li H，Zhang M，Lu Y，Hong B，Zheng Y，He J，Yang J，Yi Q.鼠TH9细胞促进癌症免疫疗法中髓样树突状细胞的生存。癌症
Immunol Immunother, 2014, 63(8): 835-845.
15. Lu Y，Zhang M，Wang S，Hong B，Wang Z，Li H，Zheng Y，Yang J，Davis R，Qian J，Hou J，Hou J，Yi Q.P38 MAPK抑制的树突状细胞可诱导上级抗肿瘤免疫反应并克服调节性T细胞介导的免疫抑制。自然通讯，2014，5：4229。
16. Hong B，Li H，Lu Y，Zhang M，Zheng Y，Qian J，Yi Q. USP18对于IFN-γ介导的B16黑色素瘤肿瘤发生和抗肿瘤免疫的抑制至关重要。分子癌，2014，13：132。
17. Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Yang J, Qian J, Yi Q.p38 MAPK inhibits breast cancer metastasis through regulating stromal expansion. Int J Cancer, 2015, 136(1):34-43.
18. Dang RJ，Yang YM，Zhang L，Cui DC，Hong B，Li P，Lin Q，Wang Y，Wang QY，Xiao F，Mao F，Mao N，Wang C，Jiang XX，Wen N. A20在间充质干细胞的免疫调节功能。J Cell Mol Med，2016，20（8）：1550-1560。
19. Huang XF，Nandakumar V，Tumurkhuu G，Wang T，Jiang XX，Hong B，Jones L，Jones L，Yoshii H，Ozato K，Masumi A，Masumi A，Chen Sy。MySM1是干扰素调节因子表达在维持HSC静止和胸腺细胞发育时所必需的。细胞死亡与疾病，2016，7（6）：E2260。
20. Wang D，Huang XF，Hong B，Song XT，Hu L，Jiang M等。细胞内免疫检查点的直流疫苗的功效。JCI Insight，2018，3（3）：E98368。
21. Hong B, Muilli K, Bolyard C, Russell L, Lee TJ, Siddegowda BS, Yoo JY, Yan Y, Ballester L, Bockhorst K, Kaur B. Suppression of HMGB1 released in the glioblastoma tumor microenvironment reduces tumoral edema. Molecular Therapy Oncolytics, 2018, 12:93-102. 22. Russell L, Swanner J, Jaime-Ramirez AC, Wang Y, Sprague A, Banasavadi-Siddegowda Y, Yoo JY, Sizemore GM, Kladney R, Zhang J, Lehman NL, Ostrowski MC, Hong B, Caligiuri M, Yu J,
Kaur B. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nature Communications, 2018, 9(1):5006.
23. Yoo JY，Swanner J，Otani Y，Nair M，Park F，Banasavadi-Siddegowda Y，Liu J，Jaime-Raimirez AC，Hong B，Hong B，Geng F，Guo D，Bystry D，Bystry D，Bystry D，Pelphs M，pelphs M，Quadri H，Quadri H，Quadri H，Lee TJ tj JJ TJ JJ，Kaur B. OHSV疗法会增加曲妥尼对脑肿瘤的访问，并在体内敏感。Neuro Oncol，2019，21（9）：1131-1140。
24. Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso N, Cruz T, Wu M, Liu H, Song X, Suzuki M, Wang L, Yustein J, Gottschalk S. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells. Advances in Cell and Gene Therapy, 2020, doi: 10.1002.
25. Hong B，Chapa V，Saini U，Modgil P，Cohn D，He G，Siddik Z，Sood A，Yan Y，Karuppaiyah S，Pei G，Zhao Z，Zhao Z，Yoo JY，Kaur b。溶瘤HSV治疗调节囊泡贩运诱导顺铂敏感性和抗肿瘤免疫。临床癌症研究，2021，27（2beplay苹果手机能用吗）：542-553。